UNSPSC 51432201: Budralazine

This classification denotes an antihypertensive agent with the molecular formula C14H16N4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier S0177QHV2B, chemically known as 1(2h)-phthalazinone, (1,3-dimethyl-2-butenylidene)hydrazone but generally known as budralazine, which bears US NIH Compound Identifier 6419536. Budralazine most often comes in base and hydrochloride forms. European Medicines Agency schedules Budralazine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05958MIG.

UNSPSC 51432201 Budralazine is a Commodity code covering pharmaceutical products supplied to state and local emergency medical services and health agencies. State and local governments procure advanced life support medications and generic multi-source pharmaceuticals under this code for use by fire rescue departments, emergency medical services, and state health benefit programs. The scope encompasses individual medication line items (such as epinephrine injections, labetalol, adenosine, and diltiazem vials) purchased in specific unit quantities with firm expiration-date requirements and rapid delivery cycles, as well as broader generic pharmaceutical supply agreements managed through cooperative purchasing vehicles. Issuing bodies include municipal fire and rescue departments, state health and human services agencies, and multistate cooperative purchasing alliances that aggregate demand across participating state and local facilities.

Recent activity spans Florida, Minnesota, and Texas. The City of Tampa's Purchasing Department issued IFB 26P00188 for Advanced Life Support Medications to supply Tampa Fire Rescue with four specific medication line items totaling approximately $40,000, with bids due April 8, 2026, and a one-year contract term plus optional two-year renewals and three 30-day unilateral extensions; the solicitation included a 5 percent bid discount for Small Local Business Enterprise participation not to exceed $10,000. The Minnesota Department of Administration's Office of State Procurement, administering the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), issued RFP S1070000015802 for Generic Multi Source Pharmaceuticals and OTC Products with a March 26, 2026 response deadline and July 1, 2026 contract effective date; the RFP covers a two-year initial term with optional extensions and evaluates vendors on pricing (75 percent weight), price format compliance, EDI capability, and fixed pricing terms. The Texas Health and Human Services Commission issued an RFI (HHS0017013) in April 2026 to gather market intelligence on direct-to-manufacturer prescription programs, signaling potential future procurement activity around alternative pharmacy supply models outside traditional wholesaler and pharmacy benefit manager arrangements.